COPD segment

To maintain its leadership in the chronic obstructive pulmonary disease (or COPD) segment, GlaxoSmithKline (GSK) has focused on shifting patients away from LAMA monotherapy to its LAMA/LABA bronchodilators, Anoro and Incruse. The company also expects to see COPD patients who are at higher risk of exacerbations to shift from open triple therapy to closed triple therapy such as the recently launched Trelegy Ellipta. GlaxoSmithKline accounts for around 0.88% of the Vanguard FTSE All-World ex-US ETF’s (VEU) total portfolio holdings.

GlaxoSmithKline Is Focused on Maintaining Leadership in This SegmentRelvar/Breo in COPD

The above diagram shows the design of Salford Lung Study, which compared the effectiveness of Revlar/Breo for COPD patients as compared to standard of care, which was either ICS/LABA therapy or triple therapy. The trial was designed to be nonselective and included patients with varying lifestyles and comorbidities. The study showed that there was an 8% drop in exacerbations in patients treated with Relvar/Breo as compared to those treated with standard of care. This implies that Relvar/Breo demonstrated significant improvement in the quality of life as compared to standard of care for COPD patients. Relvar/Breo is thus expected to enable GlaxoSmithKline to compete effectively with other COPD players such as Teva Pharmaceuticals (TEVA), Novartis (NVS), and Mylan (MYL).

Revlar/Breo revenue performance

Owing to strong demand trends in both asthma and COPD segments, Revlar/Breo Elipta earned revenues close to 710 million pounds in the first nine months of 2017, which is 72% year-over-year (or YoY) growth on a reported basis and 59% YoY growth on a constant exchange rate (or CER) basis. Revlar/Breo witnessed revenues close to 225 million pounds in 3Q17, which is a YoY rise of 44% on a reported basis and 43% on a CER basis. The true-up adjustments from sales concluded in previous quarters had a slightly negative impact on Breo’s revenue numbers in 3Q17. However, the total prescriptions and new-to-brand prescriptions for this product have continued to demonstrate a YoY rise of 74% and 24%, respectively, in 3Q17.

In the next article, we’ll discuss GlaxoSmithKline’s Anoro Ellipta and Incruse Ellipta products in greater detail.

Latest articles

Broadcom (AVGO) stock fell ~8.5% after markets closed yesterday following the semiconductor giant's fiscal 2019 second-quarter earnings release. It missed analysts' revenue estimate and cut its fiscal 2019 revenue guidance by $2 billion to $22.5 billion due to sluggishness in its semiconductor solutions business.

The SPDR Gold Shares ETF (GLD), which tracks physical gold prices, has underperformed the broader markets year-to-date, rising just 4.4% compared to the S&P 500’s (SPY) gain of 15.9% as of June 14. The sentiment for gold, however, has been turning around.

Safe havens such as Treasuries and gold were back in favor on June 14 as stocks fell due to rising tensions in the Middle East, concerns over growth, and the looming threat of the US-China trade war. The tech-heavy Nasdaq Composite Index fell 0.67% in the first hour of trading.

Lululemon (LULU) stock rose 2.1% on June 13 in reaction to better-than-expected first-quarter results and an upgraded outlook for fiscal 2019 overall. The company's first-quarter adjusted EPS grew 34.5% to $0.74 on revenue growth of 20.4% to $782.32 million. Analysts had expected EPS of $0.70 and revenue of $755.31 million. Here's why the outlook got an upgrade.

14 Jun

IEA Again Slashes Its Oil Demand Growth Estimate

WRITTEN BY Rabindra Samanta

As of 4:40 AM Eastern Time today, US crude oil active futures were at $51.83, ~4% below their closing level in the previous week. If US crude oil prices stay at those levels today, they'll mark their third week of decline in five weeks.

14 Jun

Why Kimberly-Clark Stock May Stop Rising


Kimberly-Clark (KMB) stock has risen 20.5% this year, boosted by the company’s better-than-expected sales and earnings during its last reported quarter. However, its stock could stop climbing. Here's why.